Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 15
2003 24
2004 11
2005 36
2006 46
2007 39
2008 43
2009 53
2010 48
2011 47
2012 37
2013 42
2014 55
2015 54
2016 57
2017 60
2018 56
2019 60
2020 46
2021 15
Text availability
Article attribute
Article type
Publication date

Search Results

707 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB, Kido A. Yang BB, et al. Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456630 Review.
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases in more than a dose-proportional manner, suggesting that the clearance of pegfilgrastim decreases with increased dosing. ...As a resul …
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases i …
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Aapro M, et al. Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Support Care Cancer. 2017. PMID: 28842778 Free PMC article. Review.

It was agreed that pegfilgrastim and 11 days' filgrastim have similar efficacy and safety and that pegfilgrastim is preferred to < 11 days' filgrastim (and may be preferred to 11 days' filgrastim based on adherence and convenience); pegfilgrastim is not ap

It was agreed that pegfilgrastim and 11 days' filgrastim have similar efficacy and safety and that pegfilgrastim is preferred …
Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management.
Moore DC, Pellegrino AE. Moore DC, et al. Ann Pharmacother. 2017 Sep;51(9):797-803. doi: 10.1177/1060028017706373. Epub 2017 Apr 19. Ann Pharmacother. 2017. PMID: 28423916 Review.
OBJECTIVE: To review the incidence, risk factors, and management of pegfilgrastim-induced bone pain (PIBP). DATA SOURCES: PubMed was searched from 1980 to March 31, 2017, using the terms pegfilgrastim and bone pain. ...Naproxen compared with placebo demonstrated a r …
OBJECTIVE: To review the incidence, risk factors, and management of pegfilgrastim-induced bone pain (PIBP). DATA SOURCES: PubMed was …
Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report.
Romeo C, Li Q, Copeland L. Romeo C, et al. J Oncol Pharm Pract. 2015 Aug;21(4):301-4. doi: 10.1177/1078155214527858. Epub 2014 Mar 24. J Oncol Pharm Pract. 2015. PMID: 24664474
Traditional analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, can be ineffective in severe pegfilgrastim-induced bone pain. With the high frequency of this adverse effect, it is clear that health practitioners need additional treatment options …
Traditional analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, can be ineffective in severe pegfilgrastim
Pegfilgrastim.
Curran MP, Goa KL. Curran MP, et al. Drugs. 2002;62(8):1207-13; discussion 1214-5. doi: 10.2165/00003495-200262080-00012. Drugs. 2002. PMID: 12010086 Review.
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyethylene glycol. ...Serum concentrations of pegfilgrastim remain elevated during neutropenia but decline when the neutrophil count incr
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyet
LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM. Hoy SM. BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. BioDrugs. 2019. PMID: 30887256 Review.
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to be approved in the EU. ...The tolerability and safety profile of and the incidence of anti-drug antibodies with LA-EP2006 were similar to tho …
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to b …
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B. Bond TC, et al. J Oncol Pharm Pract. 2018 Sep;24(6):412-423. doi: 10.1177/1078155217714859. Epub 2017 Jun 14. J Oncol Pharm Pract. 2018. PMID: 28614980 Free PMC article. Review.
The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgrastim. Methods Embase was searched for trials examining the efficacy/safety of lipegfilgrastim, pegfilgrastim, or filgrastim. ...Indi …
The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgr …
Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.
Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, Verschraegen C, Openshaw T, Valentine J, Eneman J, Unger P, Ades S. Moukharskaya J, et al. Support Care Cancer. 2016 Jul;24(7):3085-93. doi: 10.1007/s00520-016-3119-0. Epub 2016 Feb 19. Support Care Cancer. 2016. PMID: 26894485 Free PMC article. Clinical Trial.
PURPOSE: Bone pain is a common side effect of pegfilgrastim and can interfere with quality of life and treatment adherence. ...Patients receiving an initial dose of pegfilgrastim after chemotherapy were enrolled into the observation (OBS) stage. ...
PURPOSE: Bone pain is a common side effect of pegfilgrastim and can interfere with quality of life and treatment adherence. ...Patien …
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Kirshner JJ, McDonald MC 3rd, Kruter F, Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J, Morrow PK. Kirshner JJ, et al. Support Care Cancer. 2018 Apr;26(4):1323-1334. doi: 10.1007/s00520-017-3959-2. Epub 2017 Nov 16. Support Care Cancer. 2018. PMID: 29147854 Free PMC article. Clinical Trial.
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on pegfilgrastim-associated bone pain. METHODS: In this open-labe …
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect …
Pegfilgrastim.
Willis F, Pettengell R. Willis F, et al. Expert Opin Biol Ther. 2002 Dec;2(8):985-92. doi: 10.1517/14712598.2.8.985. Expert Opin Biol Ther. 2002. PMID: 12517276 Review.
Single dose pegfilgrastim has been shown to be as safe and effective as daily filgrastim in reducing the incidence of chemotherapy induced neutropenia. Pegfilgrastim provides clinical and quality of life benefits for patients as a result of its once per cycle admini …
Single dose pegfilgrastim has been shown to be as safe and effective as daily filgrastim in reducing the incidence of chemotherapy in …
707 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page